

---

**Specimen Collected: 7/18/2025 12:20 MDT****Quetiapine, Serum or Plasma** | **Received: 7/18/2025 12:20 MDT** | **Report/Verified: 7/18/2025 12:21 MDT**

Procedure	Result	Units	Reference Interval
Quetiapine, Serum/Plasma	150 <sup>i1</sup>	ng/mL	[100-1000]

**Test Information**

i1: Quetiapine, Serum/Plasma

INTERPRETIVE INFORMATION: Quetiapine, Serum or Plasma

Therapeutic range: 100-1000 ng/mL

Toxic: Greater than 1000 ng/mL

The therapeutic range is based on serum pre-dose (trough) draw at steady-state concentration. The pharmacokinetics of quetiapine are influenced by drug-drug interactions that may inhibit or induce CYP3A4 metabolism. Adverse effects to quetiapine therapy may include somnolence, hypotension, dizziness, neuroleptic malignant syndrome, tardive dyskinesia, and weight gain.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

---

\*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H-High, i-Test Information, L-Low, t-Interpretive Text, @=Performing lab

---

**Unless otherwise indicated, testing performed at:****ARUP Laboratories**

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

**ARUP Accession:** 25-199-900009**Report Request ID:** 20596139**Printed:** 7/18/2025 12:21 MDT

Page 1 of 1